Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-22T08:12:54.980Z Has data issue: false hasContentIssue false
  • English
  • Français

New drugs for Alzheimer's disease

Published online by Cambridge University Press:  03 January 2018

Alistair Burns ,
Eve Russell  and
Sean Rage
Alistair Burns*
Affiliation:
Department of Psychiatry, University of Manchester, Withington Hospital, Manchester
Eve Russell
Affiliation:
Department of Psychiatry, University of Manchester, Withington Hospital, Manchester
Sean Rage
Affiliation:
Department of Psychiatry, University of Manchester, Withington Hospital, Manchester
*
Professor A. Burns, Department of Psychiatry, University of Manchester, Withington Hospital, Manchester M20 8LR, UK. Tel: 0161 291 3310: Fax: 0161 291 4364
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorials
Information
The British Journal of Psychiatry , Volume 174 , Issue 6 , June 1999 , pp. 476 - 479
Copyright
Copyright © 1999 The Royal College of Psychiatrists 

References

Anand, R. & Gharabini, G. (1996) Clinical development of Exelon. The ADENA programme. Journal of Drug Development and Clinical Practice. 8, 117–122 Google Scholar
Anonymous (1998) Donepezil update. Drugs and Therapeutics Bulletin. 36, 60–61.Google Scholar
Anonymous (1999) Donepezil for Alzheimer's disease. Drugs and Therapeutics Bulletin, 35, 75–76 Google Scholar
Bosanquet, N., May, J. & Johnson, N. (1998) Alzheimer's Disease in the United Kingdom Burden of Disease and Future Care Health Policy Review Paper No. 12. London: Health Policy Unit. Imperial College School of Medicine Google Scholar
Burns, A. & Murphy, D. (1996) Protection against Alzheimer's disease Lancet 348 420–421 CrossRefGoogle ScholarPubMed
Burns, A., Rossor, M., Hecker, J., et al (1999) The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dementia and Geriatric Cognitive Disorders, 10, 237–244.Google Scholar
Committee lor Proprietary Medicinal Products (CPMP) (1997) Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease London: European Agency for the Evaluation of Medicinal Products.Google Scholar
Cummings, J., Megam, M. & Gray, K. (1994) The Neuropsychiatric Inventory. Neurology. 44. 2308–2314 Google Scholar
de Jong, R., Osterlund, O. & Roy, G. (1989) Measurement of quality of life changes in patients with Alzheimer's disease. Clinical Therapeutics, 11, 545–555.Google Scholar
Dening, T. & Lawton, C. (1998) Doctors want to offer more than sympathy. British Medical Journal, 317. 945.Google Scholar
Glennie, G. (1997) The efficacy of tacrine and the measurement of outcomes in Alzheimer's disease. In Technology Overview: Pharmaceuticals, issue 5. Ottawa: Canadian Co-ordinating Office for Health Technology Assessment.Google Scholar
Gortelmeyar, R., Kante, M., Parsons, C., et al (1993) The treatment of dementia syndrome with ecotonal memantine. In Spectrum KTRUM der Negro-rehabilitation (ed. W. Von Wild), pp. 50–56. Munich: Zuckschwerdt.Google Scholar
Harvey, R. (1999) A review and commentary on a sample of 15 UK guidelines for the drug treatment of Alzheimer's disease. International journol of Geriatric Psychiatry, in press.Google Scholar
Herman, A., Rocca, W., Brayne, C., et al (1991) The prevalence of dementia in Europe. International Journal of Epidemiology, 20, 736–748.Google Scholar
Knopman, D., Knapp, M., Gracon, S., et al (1994) The Clinician Interview Based Impression (CIBI) Neurology, 44, 2315–2321.Google Scholar
Le Bars, P., Katz, M., Berman, N., et al (1997) A placebo controlled double blind randomised trial of an extract of Ginkgo biloba for dementia. Journal of the American Medical Association, 278, 1327–1332.Google Scholar
Leber, R (1990) Guidelines for the Clinical Evaluation of Anti-Dementia Drugs. Open Letter to the Pharmaceutical Industry Washington, DC: Food and Drug Administration.Google Scholar
Lovestone, S., Graham, N. & Howard, R. (1997) Guidelines on drug treatment for Alzheimer's disease. Lancet, 350, 232–233.Google Scholar
McKeith, L. (1988) The clinical trial protocol of Metrifonate in Alzheimer's Trial (MALT). Dementia & Geriatric Cognitive Disorders, 9 (suppl. 2), 2–7.CrossRefGoogle Scholar
Morris, J., Cyrus, P., Orazem, J., et al (1998) Metrifonate benefits cognitive, behavioural and global function in patients with Alzheimer's disease. Neurology, 50, 1222–1230.CrossRefGoogle ScholarPubMed
Rogers, S. & Friedhoff, L (1996) The efficacy and safety of donepezil in patients with Alzheimer's disease. Dementia, 7, 293–303.Google Scholar
Rogers, S. & Friedhoff, L (1998) Long-term efficacy and safety of donepezil and the treatment of Alzheimer's disease. European Neuropsychopharmacology, 8, 67–75.CrossRefGoogle ScholarPubMed
Rogers, S., Fariow, M., Doody, R., et al (1998a) A 24-week double-blind placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50, 136–145.Google Scholar
Rogers, S., Doody, R., Mohs, R., et al (1998b) Donepezil improves cognition and global function in Alzheimer's disease. Archives of Internal Medicine, 158, 1021–1031.Google Scholar
Rosen, W., Mohs, R. & Davies, K. (1984) A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 1356–1364.Google Scholar
Rother, M., Eridnjunti, T., Roessner, M., et at (1998) Propentofylline in the treatment of Alzheimer's disease and vascular dementia. A review of Phase 3 trials. Dementio & Geriatric Cognitive Disorders, 9 (suppl. 1). 36–43.Google Scholar
Sana, M., Ernesto, C., Thomas, R., et al (1997) A controlled trial of selegiline, alpha tocopherol or both as treatment for Alzheimer's disease. New England Journal of Medicine, 336, 1216–1222.CrossRefGoogle Scholar
Schneider, L, Olin, J., Doody, R., et el (1997) Validity and reliability of the Alzheimer's Disease Co-Operative Study - clinical global impression of change. Alzheimer's Disease and Associated Disorders, 11 (suppl. 2). S22–S32.Google Scholar
Standbig Medical Advisory Committee (SMAC) (1998) The Use of Donepezil for Alzheimer's Disease. London: Department of Health.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.